SAN DIEGO, Sept. 13, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer, announced today that abstracts incorporating data from its HuMab-5B1 antibody, have been selected for oral and poster presentations at the 2017 World Molecular Imaging Congress (WMIC) being held September 13-16, 2017 in Philadelphia, PA.
The following oral presentations will take place:
Presenter: Nicholas Sobal, Ph.D., Research Scholar, The Jason Lewis Lab at Memorial Sloan Kettering
Abstract Title: Renally Clearable Gold Immunoconjugates for In Vivo PET/CT Imaging of Pancreatic Cancer
Date: Thursday, September 14, 2017
Time: 2:45 PM (EDT)
Presenter: Sophie Poty, Ph.D., Research Fellow, The Jason Lewis Lab at Memorial Sloan Kettering
Abstract Title: Cerenkov imaging of 225Ac-radioimmunoconjugates for targeted alpha therapy of pancreatic ductal adenocarcinoma
Date: Friday, September 15, 2017
Time: 11:15 AM (EDT)
The following poster presentations will take place:
Presenter: Wolfgang W. Scholz, Ph.D., Vice President of Antibody Discovery at MabVax Therapeutics
Poster Title: PET Imaging of GD2 Positive Patient-derived Osteosarcoma Xenografts with HuMab-1B7 and HuMab-31F9 Monoclonal Antibodies (P257)
Date: Friday, September 15, 2017
Time: 4:45-5:45 PM (EDT)
Presenter: Outi M. Keinänen, Ph.D. The Jason Lewis Lab at Memorial Sloan Kettering
Poster Title: Comparison of two fluorine-18 labeled tetrazine tracers for pretargeting of internalizing antibodies, 5B1 and cetuximab (P209)
Date: Friday, September 15, 2017
Time: 4:45-5:45 PM (EDT)
About the HuMab-5B1 Antibody
The Company's HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase 1 trial at Memorial Sloan Kettering Cancer Center (MSK). The HuMab-5B1 antibody has excellent tumor targeting capabilities, as well as being internalized by pancreatic cancer cells. These important attributes have allowed us to use the HuMab-5B1 antibody as a tumor-targeting platform upon which we have created multiple products. The antibody itself is in a Phase 1 clinical trial as a therapeutic agent.
About MabVax
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors. CA19-9 is expressed in over 90% of pancreatic cancers and in other diseases including small cell lung and GI cancers. CA19-9 plays an important role in tumor adhesion and metastasis, and is a marker of an aggressive cancer phenotype. CA19-9 serum levels are considered a valuable adjunct in the diagnosis, prognosis and treatment monitoring of pancreatic cancer. With our collaborators including Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute, Honor Health and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase 1 clinical studies, and demonstrated early safety and specificity for the target. Patient dosing has commenced for our lead development program in Phase 1 clinical study of the Company's radioimmunotherapy product MVT-1075. For additional information, please visit the Company's website, www.mabvax.com.
Forward Looking Statements:
This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to presentations at the WMIC. We have no assurance that all the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended and supplemented from time to time and the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.
Investor Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: jtc@jenenethomascommunications.com
SOURCE MabVax Therapeutics Holdings, Inc.